Skip to content
Search

Latest Stories

Ibuprofen may not harm Covid-19 patients: Study

There is no evidence for or against the use of anti-inflammatory drugs such as ibuprofen for patients with Covid-19, according to a study which assessed existing studies on other coronavirus strains as well as the limited literature on the current pandemic.

According to researchers, including those from King’s College London, other types of drugs, such as TNF blockers and JAK inhibitors are also safe to use.


The research, published in the open access cancer journal ecancermedicalscience, assessed 89 existing studies on other coronavirus strains such as MERS and SARS, as well as ones on the current pandemic to find out if certain medications used in people already suffering from diseases should be avoided if they were to catch Covid-19.

It said some patients, such as those with cancer, are already given immunosuppressive drugs to lower the body’s immune response or immunostimulant drugs to boost it.

If these patients then catch Covid-19, doctors need to know what medication to use, the researchers explained.

Mieke Van Hemelrijck, a cancer epidemiologist and an author of the study, said: “This pandemic has led to challenging decision-making about the treatment of Covid-19 patients who were already critically unwell.

“In parallel, doctors across multiple specialties are making clinical decisions about the appropriate continuation of treatments for patients with chronic illnesses requiring immune suppressive medication.”

While there had been some speculation that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen might make the symptoms worse for some Covid-19 patients, the researchers said they did not find evidence to support this statement.

Study co-author Sophie Papa commented: “Current evidence suggests that low dose prednisolone (a steroid used to treat allergies) and tacrolimus therapy (an immunosuppressive drug given to patients who have had an organ transplant) may have beneficial impact on the course of coronavirus infections.

However, further investigation is needed.”

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less